Viveon Health (NYSE:VHAQ) announced this morning that it has amended its combination with Clearday to double the equity consideration the target will receive to $500 million from $250 million.
This does not include options, warrants and the 5,000,000 shares Clearday shareholders may receive through an earnout if it achieves profitability over a 12-month period within five years of close.
Increasing a target’s valuation between announcement and close is relatively rare. More often, valuations go in the other direction as SPACs receive shareholder feedback and work to keep the deal attractive to investors.
Viveon Health may be less concerned about that side of the aisle as it has already experienced 91.9% redemptions through extension votes and this transaction does not have a minimum cash condition. It may now extend its deadline without further shareholder consent up to March 31, 2024.
The last major valuation bump of this kind came when Concord I boosted its valuation of crypto payments platform Circle from $4.5 billion to $9 billion in February 2022. This turned out to be unfortunate timing as the crypto market hit major headwinds shortly thereafter. The two sides terminated the deal that December, with Circle blaming a drawn-out SEC review for the collapse.
Viveon Health for its part announced this combination in April. San Antonio, Texas-based Clearday provides a suite of digital and robotics solutions aimed at providing more efficient care for seniors in assisted living facilities.
At the SPAC of Dawn The SPAC world is set to get its newest member later today when Launch Two (NASDAQ:LPBBU) begins trading having priced its $200 million IPO overnight. The technology SPAC is the first to IPO this quarter and comes after the newfound SPAC issuance momentum appeared to throttle down slightly in September,...
Launch Two Acquisition Corp. announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “LPBBU”, Tuesday, October 8, 2024. The new SPAC’s primary search focus will be on technology and software infrastructure companies whose products and services target financial services, real estate and...
Oaktree III Life Sciences (NASDAQ:OACCU) has filed for a $175 million SPAC with some of the most aggressively team-friendly terms seen so far in the second half of 2024. The new SPAC’s units contain 1/5 warrants and the trust is not set to be overfunded. Only the warrantless Cantor Equity Partners (NASDAQ:CEP) has IPO’d so...
At the SPAC of Dawn SPACs are set to have a sleepy start to their post-Rosh Hashanah week with no votes on the docket until Wednesday. Three SPACs are to hold extension votes that day and Clover Leaf (OTC:CLOE) will try again to close its combination with Kustom Entertainment after several adjournments on Friday. In...
Terms Tracker for the Week Ending October 4, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This week was much, much heavier on the S-1 filings. There were five new SPACs filed along with six amended S-1 registration statements making good...